Minimally invasive rectal cancer surgery after neoadjuvant therapy in selected elderly and frail patients: A single-center real-world experience

Table 1 Baseline characteristics stratified by age group, n (%)/mean ± SD

Variable	Age ≥ 80 years (n = 23)	Age < 80 years (n = 119)	P value
Body mass index	26.3 ± 4.0	25.4 ± 4.2	-
ACCI	11.2 ± 1.9	6.7 ± 2.9	< 0.001
ASA score	3.0 ± 0.2	2.4 ± 0.6	< 0.001
Male sex	14 (60.9)	72 (60.5)	0.98
Comorbidities ≥ 1	18 (78.3)	54 (45.4)	< 0.01
Previous surgery	5 (21.7)	30 (25.2)	0.72
Smoking	3 (13.0)	36 (31.1)	0.10
Frail (mFI-5 ≥ 2)	5 (21.7)	11 (9.2)	0.09
Neoadjuvant treatment
CH-RT	21 (91.3)	79 (66.4)	0.02
TNT	2 (8.7)	40 (33.6)	0.02
Chemotherapy backbone
Fluoropyrimidine-based	16 (88.9)	67 (63.8)	-
Oxaliplatin-based	1 (5.6)	33 (31.4)	-
Irinotecan-based	1 (5.6)	5 (4.8)	-
Biologic therapy	2 (11.1)	14 (13.3)	-

ACCI: Age-Adjusted Charlson Comorbidity Index; ASA: American Society of Anesthesiologists; mFI: 5-item modified frailty index; CH-RT: Chemoradiotherapy; TNT: Total neoadjuvant therapy.